Skip to content

Examination of the usefulness of new dosage forms for external preparation (frothiness sprays) of the heparin similar material agent

Examination of the usefulness of new dosage forms for external preparation (frothiness sprays) of the heparin similar material agent - Usefulness examination of the Form Spray

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027664
Enrollment
40
Registered
2017-06-09
Start date
2017-04-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dry skin

Interventions

4 weeks, appropriate amount, appropriately

Sponsors

Non-Profit Organization Health Institute Research of Skin
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) The patients who it present a skin drying symptom, and are treated for a heparin similar material agent for external preparation. 2) The patients that an agreement were provided in a document after having explained this study contents.

Exclusion criteria

Exclusion criteria: 1) Patients who are treated for an agent for anti-inflammatory external preparation, and they visit a hospital for treatment regularly. 2) Patients with hemorrhagic blood disorder 3) Patient that it are expected that little bleeding causes a serious result. 4) Patients who use a steroid or anti-allergic drug. 5) Patients with a medical history of the serious disease. 6) Patients who have difficulty in patient diary entry. 7) A pregnant woman or the woman who may be pregnant and the woman whom I am nursing. The patient who hopes for the pregnancy during a study period. 8) The patients that the co-investigator judged this study enforcement to be inappropriate. 9) The patients who participate in other clinical trials for the past three months.

Design outcomes

Primary

MeasureTime frame
Rate of change of the water content in epidermal stratum corneum of 4 weeks

Secondary

MeasureTime frame
Usability of the patient

Countries

Japan

Contacts

Public ContactYoshitaka Ogaki

EBC&M LLC. Project planning & Development department

yoshitaka_ogaki@ebc-m.com03-6435-3833

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026